Loading...

BRAINSTORM CELL THERAPEUTICS INC Financial Troubles 8-K Filing

BRNS

BRAINSTORM CELL THERAPEUTICS INC

()

2025 8-K

Financial Results Announcement

Securities Agreement

Equity Offering Details

Funding Agreement

Financial Agreement

Financial Results Announced

Voluntary Delisting

Management Changes

Financial Statements

Bylaws Amendment

Financial Results

Warrant Agreement

Nasdaq Compliance Extension

Nasdaq Delisting Appeal

Nasdaq Delisting Notice

Financial Results

Nasdaq Compliance

Company Presentation

Stock Split Announcement

Shareholder Approvals

Financial Results

Announcement of Annual Meeting

Delisting Notice

Securities Purchase Agreement

FDA Alignment for NurOwn Ph...

Appointment of Dr. Hartoun ...

Management Changes

Compliance regained with Mi...

FDA Agreement for Phase 3b ...

Distribution Agreement Amen...

Financial Results Announcement

Annual Meeting of Stockholders

FDA Meeting for NurOwn in ALS

Delisting Notice

Delisting Notice

Costs Associated with Exit ...

Equity Offerings

Resignation and Appointment...

FDA Review of ALS Stem Cell...

Financial Results Announcement

FDA Advisory Committee Meet...

Annual Meeting of Stockholders

Amendment and Separation Ag...

External Links:

On May 19, 2025, Brainstorm Cell Therapeutics Inc. announced it received FDA clearance to begin its Phase 3b clinical trial for NurOwn®, a treatment for ALS.

AI Assistant

BRAINSTORM CELL THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.